MacDonald S, Byrd C, Barlow E, Nahar V K, Martin J, Krenk D
East Tennessee State University, Quillen College of Medicine, Orthopedic Residency, Johnson City, TN, USA.
University of Mississippi Medical Center, Jackson, MS, USA.
Adv Orthop. 2022 Jun 2;2022:8276065. doi: 10.1155/2022/8276065. eCollection 2022.
Over the past 50 years, treatment of displaced acetabular fractures has moved away from conservative treatment with bedrest to operative intervention to achieve anatomic reduction, stable fixation, and allow early range of motion of the hip. However, operative fixation is not without complications. Internal fixation of traumatic acetabular fractures has been coupled with large volume of blood loss both at the time of injury and surgery. This often results in the need for allogenic blood products, which has been linked to increase morbidity (Vamvakas and Blajchman, 2009). In an attempt to avoid the risk associated with allogenic blood transfusion numerous techniques and methods have been devised. Red blood cell salvage (CS) is an intraoperative blood salvage tool where blood is harvested from the operative field. It is washed to remove the plasma, white blood cells, and platelets. The red cells are resuspended in a crystalloid solution. If the hematocrit of the resuspended red blood cells is sufficient, it is transfused to the patient intravenously. The benefits of CS in major spine surgery, bilateral knee replacement, and revision hip surgery are well established (Goulet et al. 1989, Gee et al. 2011, Canan et al. 2013). However, literature reviewing the use of cell saver in orthopedic trauma surgery, specifically acetabular surgery is limited. Our institute performed a retrospective review of 63 consecutive operative acetabular fractures at a level one trauma center. Our study revealed that patients with blood loss of less than 400 mL were 13 times less likely to receive autologous blood, and patients with hemoglobin less than 10.5 were 5 times less likely to receive autologous transfusion ( < 0.05). We also found that no patients with a hemoglobin level less than 10.5 and EBL less than 400 mL received autologous blood return. Autologous blood transfusion had no effect on volume or rate of allogenic blood transfusion. We believed that if a patient's preoperative hemoglobin is less than 10.5 or expected blood loss is less than 400 mL, then CS should have a very limited role, if any, in the preoperative blood conservation strategy. We found ASA greater than 2, BMI greater than 24 and associated fracture type to be a risk factor for high blood loss.
在过去50年里,移位髋臼骨折的治疗已从卧床休息的保守治疗转向手术干预,以实现解剖复位、稳定固定,并允许髋关节早期活动。然而,手术固定并非没有并发症。创伤性髋臼骨折的内固定在受伤时和手术时都伴随着大量失血。这通常导致需要异体血制品,而异体血制品与发病率增加有关(Vamvakas和Blajchman,2009年)。为了避免与异体输血相关的风险,人们设计了许多技术和方法。红细胞回收(CS)是一种术中血液回收工具,从手术区域收集血液。对其进行清洗以去除血浆、白细胞和血小板。红细胞被重新悬浮在晶体溶液中。如果重新悬浮的红细胞的血细胞比容足够,则通过静脉输给患者。CS在脊柱大手术、双侧膝关节置换和髋关节翻修手术中的益处已得到充分证实(Goulet等人,1989年;Gee等人,2011年;Canan等人,2013年)。然而,关于细胞回收器在骨科创伤手术,特别是髋臼手术中的应用的文献有限。我们研究所对一家一级创伤中心连续63例手术治疗的髋臼骨折进行了回顾性研究。我们的研究表明,失血少于400毫升的患者接受自体血的可能性低13倍,血红蛋白低于10.5的患者接受自体输血的可能性低5倍(P<0.05)。我们还发现,血红蛋白水平低于10.5且估计失血量少于400毫升的患者中,没有患者接受自体血回输。自体输血对异体输血的量或速度没有影响。我们认为,如果患者术前血红蛋白低于10.5或预期失血量少于400毫升,那么CS在术前血液保护策略中的作用将非常有限(如果有作用的话)。我们发现美国麻醉医师协会(ASA)分级大于2、体重指数(BMI)大于24以及相关骨折类型是高失血量的危险因素。